drugset / Trial / NCT01015495

Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks

NCT01015495

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether injections of ranibizumab into the eye are safe and well tolerated when given to subjects in multiple doses.

Timeline

Start
2009-12
Primary completion
2010-12
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal

Indications